Threshold Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic and diagnostic agents that target tumor cells for the treatment of cancer patients in the United States. It is developing evofosfamide, which is in two Phase III clinical trials for the treatment of soft tissue sarcoma indication and advanced pancreatic cancer; and Phase II clinical trials for the treatment of prostate cancer, pancreatic cancer, melanoma, and HPV negative squamous cell cancer of head and neck. The companyÂ’s evofosfamide is also involved in the Phase I clinical trials for the treatment of patients with advanced renal cell carcinoma, gastrointestinal stromal tumors, and pancreatic neuroendocrine tumors; Phase I/II clinical trials for glioblastoma; Phase I clinical trials for advanced solid tumors; Phase II clinical trials for glioblastoma and pancreatic neuroendocrine tumors; Phase I/II clinical trials for advanced kidney cancer or liver cancer; and Phase II clinical trials for the treatment of advanced biliary tract cancer. In addition, it engages in developing Tarloxotinib, a hypoxia-activated EGFR tyrosine kinase inhibitor, which is in two Phase II clinical trials for patients with mutant EGFR-positive, T790M-negative advanced non-small cell lung cancer, as well as patients with metastatic squamous cell carcinomas of the head, neck, or skin; and [18F]-HX4, an investigational positron emission tomography imaging agent for hypoxia. The company has a license agreement with Merck KGaA to co-develop and commercialize evofosfamide; Auckland UniServices Ltd. for the development program based on Tarloxotinib; and Eleison Pharmaceuticals, Inc. for the manufacture, development, and commercialization of glufosfamide for the treatment of cancer in humans and animals, as well as other uses. Threshold Pharmaceuticals, Inc. was founded in 2001 and is headquartered in South San Francisco, California.
